Improved Symptom Change Enhances Quality of Dying in Patients With Advanced Cancer: An East Asian Cross-Cultural Study

• Published in: The oncologist (Dayton, Ohio) Ohio), 2024-04, Vol.29 (4), p.e553-e560
• Main Authors: Huang, Hsien-Liang, Chen, Ping-Jen, Mori, Masanori, Suh, Sang-Yeon, Wu, Chien-Yi, Peng, Jen-Kuei, Shih, Chih-Yuan, Yao, Chien-An, Tsai, Jaw-Shiun, Chiu, Tai-Yuan, Hiratsuka, Yusuke, Kim, Sun-Hyun, Morita, Tatsuya, Yamaguchi, Takashi, Tsuneto, Satoru, Hui, David, Cheng, Shao-Yi
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Cancer patients; Care and treatment; Cross-Cultural Comparison; Delirium; Dyspnea; East Asian People; Female; Humans; Male; Middle Aged; Neoplasms - psychology; Original; Palliative Care - psychology; Palliative treatment; Prospective Studies; Quality management; Terminal Care - psychology; Terminally ill persons
• ISSN: 1083-7159; 1549-490X
• DOI: 10.1093/oncolo/oyad269

Symptom burdens tend to increase for patients with cancer and their families over the disease trajectory. There is still a lack of evidence on the associations between symptom changes and the quality of dying and death. In this context, this research investigated how symptom changes influence the quality of dying and death. This international prospective cohort study (the East Asian Collaborative Cross-Cultural Study to Elucidate the Dying Process (EASED), 2017-2019) included 22, 11, and 4 palliative care units across Japan, South Korea, and Taiwan. Eligible participants were adults (Japan and Korea, ≥18 years; Taiwan, ≥20 years) with locally advanced or metastatic cancer. Physical and psychological symptoms were assessed by physicians upon admission and within 3 days before death. Death quality was assessed using the Good Death Scale (GDS), developed in Taiwan. Univariate and multivariate regression analyses were used to identify correlations between symptom severity changes and GDS scores. Among 998 patients (542 [54.3%] men and 456 [45.7%] women; mean [SD] age = 70.1 [± 12.5] years), persistent dyspnea was associated with lower GDS scores when compared to stable dyspnea (β = -0.427, 95% CI = -0.783 to -0.071). Worsened (-1.381, -1.932 to -0.831) and persistent (-1.680, -2.701 to -0.659) delirium were also significantly associated with lower GDS scores. Better quality of dying and death was associated with improved symptom control, especially for dyspnea and delirium. Integrating an outcome measurement for the quality of dying and death is important in the management of symptoms across the disease trajectory in a goal-concordant manner.